FUDAN ZHANGJIANG (01349) released its 2024 annual performance report, with a net profit attributable to shareholders of 39.73 million yuan, a year-on-year decrease of 63.42%.

FUDANZHANGJIANG (01349) announced its performance report for the year 2024, with operating income of 709 million RMB, a decrease of 16.61% year-on-year; net profit attributable to shareholders of the listed company was 39.7339 million RMB, a decrease of 63.42% year-on-year; basic earnings per share were 0.04 RMB. During the reporting period, the group actively promoted the progress of R&D projects. The FDA018 antibody-drug conjugate (anti-Trop2 antibody conjugated SN38) project entered Phase III clinical trials, with over forty clinical trial centers initiated during the reporting period and the first subject enrolled in August 2024. The FZ-AD005 antibody-drug conjugate (anti-DLL3 antibody conjugated BB05) project entered Phase I clinical trials, with the first subject enrolled in July 2024. Several other R&D projects within the group also progressed smoothly. In addition, the group's wholly-owned subsidiary, Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd., officially started operation of a new ADC production base during the reporting period and successfully scaled up production processes for two ADC projects, preparing multiple batches of samples. As a result, R&D expenses during the reporting period (including clinical trials, research materials, and outsourced R&D expenses) showed significant growth compared to the same period last year. During the reporting period, the group's production and operation remained normal, with no significant changes in the main marketed drugs. Following the termination of cooperation with a promotional services provider, sales of one of the main products, Ribavirin, decreased, leading to a certain decrease in total operating income for the group compared to the same period last year.